CFTR and Duchenne muscular dystrophy: This unwanted therapeutic outcome is highlighted in previously published studies in gene replacement studies in Duchenne muscular dystrophy patients (Mendell et al., 2010) and cystic fibrosis transmembrane conductance regulator (CFTR) knock‐out mice (Limberis et al., 2007).